首页> 美国卫生研究院文献>Journal of Clinical Oncology >Significant and Sustained Antitumor Activity in Post-Docetaxel Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

【2h】

Significant and Sustained Antitumor Activity in Post-Docetaxel Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

机译：CYP17抑制剂醋酸阿比特龙酯在多西他赛后去势抵抗性前列腺癌中的重要且持续的抗肿瘤活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeThe principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC).

机译：目的本试验的主要目的是评估多巴他赛治疗的去势抵抗性前列腺癌（CRPC）患者中的乙酸阿比特龙酯（一种口服，特异性，不可逆的CYP17抑制剂）的抗肿瘤活性。

著录项

期刊名称 Journal of Clinical Oncology
作者
Alison H.M. Reid; Gerhardt Attard; Daniel C. Danila; Nikhil Babu Oommen; David Olmos; Peter C. Fong; L. Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F. Swennenhuis; Leon W.M.M. Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J. Ryan; Eric Small; Howard I. Scher; Johann S. de Bono;
展开▼
作者单位

展开▼
年(卷),期 -1(28),9
年度 -1
页码 1489–1495
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. [J] . Reid AH, Attard G, Danila DC, Journal of Clinical Oncology . 2010,第9期

机译：CYP17抑制剂醋酸阿比特龙酯在多西他赛后去势抵抗性前列腺癌中具有显着且持续的抗肿瘤活性。
2. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. [J] . Ryan CJ, Smith MR, Fong L, Journal of Clinical Oncology . 2010,第9期

机译：CYP17抑制剂乙酸阿比特龙酯的I期临床试验证明了在接受酮康唑治疗的去势抵抗性前列腺癌患者中的临床活性。
3. 158 POSTER Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy- naive and docetaxel treated castration-resistant prostate cancer (CRPC) [J] . G.Attard, A.Reid, N.Babu Oommen, European Journal of Cancer Supplements . 2008,第12期

机译：158 POSTER乙酸阿比特龙酯（AA）是CYP17的不可逆抑制剂，在未经化疗和多西他赛治疗的去势抵抗性前列腺癌（CRPC）中均具有显着且持久的抗肿瘤活性。
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Integrin alpha6 Activity in Castration-Resistant Prostate Cancer. [D] . Nollet, Eric A. 2017

机译：整合素α6活性在去势抵抗性前列腺癌中的作用。
6. Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy [O] . Charles J. Ryan, Matthew R. Smith, Lawrence Fong, -1

机译：CYP17抑制剂醋酸阿比特龙酯的I期临床试验证明了在接受酮康唑治疗的去势抵抗性前列腺癌患者中的临床活性
7. Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate [O] . Reid, Alison H.M., Attard, Gerhardt, Danila, Daniel C., 2010

机译：CYP17抑制剂醋酸阿比特龙酯在多西他赛后，去势抵抗性前列腺癌中的重要且持续的抗肿瘤活性

Significant and Sustained Antitumor Activity in Post-Docetaxel Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅